Overview

A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma

Status:
Withdrawn
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and tolerability of 8.0 mg of ASM8 when given daily for 14 days by the Aeroneb® Go nebulizer to subjects with moderate to severe asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Pharmaxis